维普期刊资源整合服务平台（V6.5）

66篇 您的检索式：作者名="BURGESS DS"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Comparison of β-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacody- namics显示文摘	Burgess DS Fret CR	2005	J Antimicrob Chemother2005，56，10：	1
2	Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation 显示文摘	Frei RC Wiederhold NP Burgess DS	2008	J Antimicrob Chemother2008，61，4：	1
3	Antimicrobial breakpoints for gram-negarive aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation显示文摘	Frei CR Wiederhold NP Burgess DS	2008	Antimicrob Chemother2008，61，3：	1
4	Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing显示文摘	Burgess DS Waldrep P	2002	Clin Ther2002，24，7：	1
5	Antibiotic cycling to decrease bacterial antibiotic resistance : a 5-year experience on a bone marrow transplsplant unit 显示文摘	Cadena J Tabouda CA Burgess DS	2007	Bone Marrow Transplantation2007，40，2：	1
6	Treatment of Klebsiclla pneumoniae carbapenemase (KPC) infections: a review of published case series and ease reports 显示文摘	Lee GC Burgess DS	2012	Ann Clin Microbiol Antimicrob2012，11，：	1
7	Pharmacodynamic principles of adults therapy in the prevention of resistance显示文摘	BURGESS DS	1999	Chest1999，115，35：	1
8	Pharmacodynamic analysis of ceftriaxone,gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation显示文摘	FREI CR BURGESS DS	2005	Pharmacotherapy2005，25，9：	1
9	Pharmaco- dynamics of fluconazole, itraconazole, and amphotericin B against candida albicans显示文摘	Burgess DS Hastings RW Summers KK	2000	Diagn Microbiol lnfect Dis2000，36，1：	1
10	Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation显示文摘	Frei CR Wiederhold NP Burgess DS	2008	J Antimicrob Chemother2008，61，3：	1
11	Extended - spectrum beta - lactamases epidemiology detection and treatment 显示文摘	Nathisuwan S Burgess DS Lewis JS	2001	Pharmacotherapy2001，21，8：	1
12	Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing显示文摘	Burgess DS Waldrep T	2002	Clin Ther2002，24，7：	1
13	Cost effectiveness of 4 empiric antimi erobial regimens in patients with communily acquired pneumo nia显示文摘	Frei CR Burgess DS	2005	Formulary2005，156，29：	1
14	Pharmacodynamics of fluconazole, itraconazole, and amphoterlcin B against Candida albicans 显示文摘	Burgess DS Hastings RW Summers KK	2000	Diagn Microbiol Infect Dh2000，36，：	1
15	Effect of maerolides as part of initial empiric therapy on medical outcomes for hospital-ized patients with community-acquired pneumonia显示文摘	Burgess DS Lewis JS2nd	2000	Cl-in Ther2000，22，7：	1
16	Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam And cefepim against beta-lactamase-producing organisms显示文摘	Reese AM Frei CR Burgess DS	2005	Antimicrob Agents2005，26，2：	1
17	Treatment of Klebsiella pneumoniae carbapene- mase (KPC) infections: a review of published case series and ease reports显示文摘	Lee GC Burgess DS	2012	Miecobiol Antimicrob2012，11，：	1
18	Clinical and microbiologic analysis of a hospital's extended-spectrum beta- lactamase-producing isolates over a 2-year period显示文摘	Burgess DS Hall RG 2nd Lewis JS 2nd	2003	Pharmacotherapy2003，23，10：	1
19	Pharmaeodynamics of fluconazole, itraconazole, and amphotericin B against Candida albieans显示文摘	Burgess DS Hastings RW Summers KK	2000	Diagn Microbiol Infect Dis2000，36，：	1
20	Antimicrobial breakpoints for gram- negative aerobic bacteria based on pharmacokinetic-phar- macodynamic models with Monte Carlo simulation显示文摘	Frei CR Wiederhold NP Burgess DS	2008	JAC2008，61，3：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示